Hikma Slashes Generics Forecast After Key Product Delay

Expected US Launch Of Authorized Generic Xyrem Slips To As Late As 2023

05 May 2022

Just days after forecasting healthy generics sales growth for 2022, Hikma has significantly reduced its expectations for the year on news of a delay to its US launch of an authorized generic of Xyrem (sodium oxybate).

Cut Dollars Slash Sales Forecast — Hikma has cut its generics sales expectations • Source: Maren Winter / Alamy Stock Photo

Hikma has slashed its annual forecast for its US generics business, wiping around $150m off its expected sales for this year following news of a delay to the launch of an authorized generic version of Xyrem (sodium oxybate) that the company had been expecting to introduce midway through 2022.

Noting that originator Jazz had provided an “update to its expectations for the launch timing of an authorized generic of...